My name is John Mulligan, a journalist with the Sunday Tribune newspaper in Dublin. I'm writing a piece for this Sunday on Tysabri and am hoping to speak to someone who may have been involved in trials, or who was receiving the treatment prior to its withdrawl. I'd like to chat to you about how effective the treatment was for you, and your thoughts on it being pulled.
I realise for many of you this is an anxious time, but would greatly appreciate getting to speak to someone who would be willing to be identified in an article, perhaps even just by their first name if necessary.
I spoke yesterday to a physician who is a director of a center where some of the initial Natalizumab trials took place and it would be nice to be able to get a patient view too. My email address is firstname.lastname@example.org
You can email me, or whatever, and I can telephone you for a quick chat.
Looking forward to hearing from you,